Targeting NF-κB in Waldenstrom macroglobulinemia

Xavier Leleu, Jérôme Eeckhoute, Xiaoying Jia, Aldo M. Roccaro, Anne Sophie Moreau, Mena Farag, Antonio Sacco, Hai T. Ngo, Judith Runnels, Molly R. Melhem, Nicolas Burwick, Abdelkareem Azab, Feda Azab, Zachary Hunter, Evdoxia Hatjiharissi, Daniel R. Carrasco, Steven P. Treon, Thomas Elmer Witzig, Teru Hideshima, Myles BrownKenneth C.Anderson, Irene M. Ghobrial

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

The nuclear factor-κ-B (NF-κB) pathway has been implicated in tumor B-cell survival, growth, and resistance to therapy. Because tumor cells overcome single-agent antitumor activity, we hypothesized that combination of agents that target differentially NF-κB pathway will induce significant cytotoxicity. Therapeutic agents that target proteasome and Akt pathways should induce significant activity in B-cell malignancies as both pathways impact NF-κB activity. We demonstrated that perifosine and bortezomib both targeted NF-κB through its recruitment to the promoter of its target gene IκB using chromatin immunoprecipitation assay. This combination led to synergistic cytotoxicity in Waldenstrom macroglobulinemia (WM) cells that was mediated through a combined reduction of the PI3K/Akt and ERK signaling pathways, found to be critical for survival of WM cells. Moreover, a combination of these drugs with the CD20 monoclonal antibody rituximab further increased their cytotoxic activity. Thus, effective WM therapy may require combination regimens targeting the NF-κB pathway.

Original languageEnglish (US)
Pages (from-to)5068-5077
Number of pages10
JournalBlood
Volume111
Issue number10
DOIs
StatePublished - May 15 2008

Fingerprint

Waldenstrom Macroglobulinemia
Cytotoxicity
Tumors
Cells
Cell growth
B-Lymphocytes
Drug Combinations
Proteasome Endopeptidase Complex
Phosphatidylinositol 3-Kinases
Antineoplastic Agents
Chromatin
Assays
Neoplasms
MAP Kinase Signaling System
Genes
Chromatin Immunoprecipitation
Monoclonal Antibodies
Cell Survival
Therapeutics
Growth

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Leleu, X., Eeckhoute, J., Jia, X., Roccaro, A. M., Moreau, A. S., Farag, M., ... Ghobrial, I. M. (2008). Targeting NF-κB in Waldenstrom macroglobulinemia. Blood, 111(10), 5068-5077. https://doi.org/10.1182/blood-2007-09-115170

Targeting NF-κB in Waldenstrom macroglobulinemia. / Leleu, Xavier; Eeckhoute, Jérôme; Jia, Xiaoying; Roccaro, Aldo M.; Moreau, Anne Sophie; Farag, Mena; Sacco, Antonio; Ngo, Hai T.; Runnels, Judith; Melhem, Molly R.; Burwick, Nicolas; Azab, Abdelkareem; Azab, Feda; Hunter, Zachary; Hatjiharissi, Evdoxia; Carrasco, Daniel R.; Treon, Steven P.; Witzig, Thomas Elmer; Hideshima, Teru; Brown, Myles; C.Anderson, Kenneth; Ghobrial, Irene M.

In: Blood, Vol. 111, No. 10, 15.05.2008, p. 5068-5077.

Research output: Contribution to journalArticle

Leleu, X, Eeckhoute, J, Jia, X, Roccaro, AM, Moreau, AS, Farag, M, Sacco, A, Ngo, HT, Runnels, J, Melhem, MR, Burwick, N, Azab, A, Azab, F, Hunter, Z, Hatjiharissi, E, Carrasco, DR, Treon, SP, Witzig, TE, Hideshima, T, Brown, M, C.Anderson, K & Ghobrial, IM 2008, 'Targeting NF-κB in Waldenstrom macroglobulinemia', Blood, vol. 111, no. 10, pp. 5068-5077. https://doi.org/10.1182/blood-2007-09-115170
Leleu X, Eeckhoute J, Jia X, Roccaro AM, Moreau AS, Farag M et al. Targeting NF-κB in Waldenstrom macroglobulinemia. Blood. 2008 May 15;111(10):5068-5077. https://doi.org/10.1182/blood-2007-09-115170
Leleu, Xavier ; Eeckhoute, Jérôme ; Jia, Xiaoying ; Roccaro, Aldo M. ; Moreau, Anne Sophie ; Farag, Mena ; Sacco, Antonio ; Ngo, Hai T. ; Runnels, Judith ; Melhem, Molly R. ; Burwick, Nicolas ; Azab, Abdelkareem ; Azab, Feda ; Hunter, Zachary ; Hatjiharissi, Evdoxia ; Carrasco, Daniel R. ; Treon, Steven P. ; Witzig, Thomas Elmer ; Hideshima, Teru ; Brown, Myles ; C.Anderson, Kenneth ; Ghobrial, Irene M. / Targeting NF-κB in Waldenstrom macroglobulinemia. In: Blood. 2008 ; Vol. 111, No. 10. pp. 5068-5077.
@article{490ffcd16eaa453d883a32d9eba45bce,
title = "Targeting NF-κB in Waldenstrom macroglobulinemia",
abstract = "The nuclear factor-κ-B (NF-κB) pathway has been implicated in tumor B-cell survival, growth, and resistance to therapy. Because tumor cells overcome single-agent antitumor activity, we hypothesized that combination of agents that target differentially NF-κB pathway will induce significant cytotoxicity. Therapeutic agents that target proteasome and Akt pathways should induce significant activity in B-cell malignancies as both pathways impact NF-κB activity. We demonstrated that perifosine and bortezomib both targeted NF-κB through its recruitment to the promoter of its target gene IκB using chromatin immunoprecipitation assay. This combination led to synergistic cytotoxicity in Waldenstrom macroglobulinemia (WM) cells that was mediated through a combined reduction of the PI3K/Akt and ERK signaling pathways, found to be critical for survival of WM cells. Moreover, a combination of these drugs with the CD20 monoclonal antibody rituximab further increased their cytotoxic activity. Thus, effective WM therapy may require combination regimens targeting the NF-κB pathway.",
author = "Xavier Leleu and J{\'e}r{\^o}me Eeckhoute and Xiaoying Jia and Roccaro, {Aldo M.} and Moreau, {Anne Sophie} and Mena Farag and Antonio Sacco and Ngo, {Hai T.} and Judith Runnels and Melhem, {Molly R.} and Nicolas Burwick and Abdelkareem Azab and Feda Azab and Zachary Hunter and Evdoxia Hatjiharissi and Carrasco, {Daniel R.} and Treon, {Steven P.} and Witzig, {Thomas Elmer} and Teru Hideshima and Myles Brown and Kenneth C.Anderson and Ghobrial, {Irene M.}",
year = "2008",
month = "5",
day = "15",
doi = "10.1182/blood-2007-09-115170",
language = "English (US)",
volume = "111",
pages = "5068--5077",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Targeting NF-κB in Waldenstrom macroglobulinemia

AU - Leleu, Xavier

AU - Eeckhoute, Jérôme

AU - Jia, Xiaoying

AU - Roccaro, Aldo M.

AU - Moreau, Anne Sophie

AU - Farag, Mena

AU - Sacco, Antonio

AU - Ngo, Hai T.

AU - Runnels, Judith

AU - Melhem, Molly R.

AU - Burwick, Nicolas

AU - Azab, Abdelkareem

AU - Azab, Feda

AU - Hunter, Zachary

AU - Hatjiharissi, Evdoxia

AU - Carrasco, Daniel R.

AU - Treon, Steven P.

AU - Witzig, Thomas Elmer

AU - Hideshima, Teru

AU - Brown, Myles

AU - C.Anderson, Kenneth

AU - Ghobrial, Irene M.

PY - 2008/5/15

Y1 - 2008/5/15

N2 - The nuclear factor-κ-B (NF-κB) pathway has been implicated in tumor B-cell survival, growth, and resistance to therapy. Because tumor cells overcome single-agent antitumor activity, we hypothesized that combination of agents that target differentially NF-κB pathway will induce significant cytotoxicity. Therapeutic agents that target proteasome and Akt pathways should induce significant activity in B-cell malignancies as both pathways impact NF-κB activity. We demonstrated that perifosine and bortezomib both targeted NF-κB through its recruitment to the promoter of its target gene IκB using chromatin immunoprecipitation assay. This combination led to synergistic cytotoxicity in Waldenstrom macroglobulinemia (WM) cells that was mediated through a combined reduction of the PI3K/Akt and ERK signaling pathways, found to be critical for survival of WM cells. Moreover, a combination of these drugs with the CD20 monoclonal antibody rituximab further increased their cytotoxic activity. Thus, effective WM therapy may require combination regimens targeting the NF-κB pathway.

AB - The nuclear factor-κ-B (NF-κB) pathway has been implicated in tumor B-cell survival, growth, and resistance to therapy. Because tumor cells overcome single-agent antitumor activity, we hypothesized that combination of agents that target differentially NF-κB pathway will induce significant cytotoxicity. Therapeutic agents that target proteasome and Akt pathways should induce significant activity in B-cell malignancies as both pathways impact NF-κB activity. We demonstrated that perifosine and bortezomib both targeted NF-κB through its recruitment to the promoter of its target gene IκB using chromatin immunoprecipitation assay. This combination led to synergistic cytotoxicity in Waldenstrom macroglobulinemia (WM) cells that was mediated through a combined reduction of the PI3K/Akt and ERK signaling pathways, found to be critical for survival of WM cells. Moreover, a combination of these drugs with the CD20 monoclonal antibody rituximab further increased their cytotoxic activity. Thus, effective WM therapy may require combination regimens targeting the NF-κB pathway.

UR - http://www.scopus.com/inward/record.url?scp=46749129422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46749129422&partnerID=8YFLogxK

U2 - 10.1182/blood-2007-09-115170

DO - 10.1182/blood-2007-09-115170

M3 - Article

C2 - 18334673

AN - SCOPUS:46749129422

VL - 111

SP - 5068

EP - 5077

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -